These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 32188379)

  • 1. Nanomedicines in Diagnosis and Treatment of Cancer: An Update.
    Haider N; Fatima S; Taha M; Rizwanullah M; Firdous J; Ahmad R; Mazhar F; Khan MA
    Curr Pharm Des; 2020; 26(11):1216-1231. PubMed ID: 32188379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise.
    Bharali DJ; Mousa SA
    Pharmacol Ther; 2010 Nov; 128(2):324-35. PubMed ID: 20705093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives.
    Cheng Y; Zhao L; Li Y; Xu T
    Chem Soc Rev; 2011 May; 40(5):2673-703. PubMed ID: 21286593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surface-Engineered Cancer Nanomedicine: Rational Design and Recent Progress.
    Ahmad J; Ameeduzzafar ; Ahmad MZ; Akhter H
    Curr Pharm Des; 2020; 26(11):1181-1190. PubMed ID: 32056517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of next generation nanomedicine-based approaches for the treatment of cancer: we've barely scratched the surface.
    Tracey SR; Smyth P; Barelle CJ; Scott CJ
    Biochem Soc Trans; 2021 Nov; 49(5):2253-2269. PubMed ID: 34709394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect.
    Sajja HK; East MP; Mao H; Wang YA; Nie S; Yang L
    Curr Drug Discov Technol; 2009 Mar; 6(1):43-51. PubMed ID: 19275541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surface engineered multifunctional nano-systems for localised drug delivery against thyroid cancer: A review of current practices.
    Zhang Y; Tang N; Zhou H; Zhu Y
    Biomed Pharmacother; 2024 Jul; 176():116840. PubMed ID: 38820975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes.
    Palazzolo S; Bayda S; Hadla M; Caligiuri I; Corona G; Toffoli G; Rizzolio F
    Curr Med Chem; 2018; 25(34):4224-4268. PubMed ID: 28875844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles.
    Liu Y; Miyoshi H; Nakamura M
    Int J Cancer; 2007 Jun; 120(12):2527-37. PubMed ID: 17390371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aptamer-guided nanomedicines for anticancer drug delivery.
    Alshaer W; Hillaireau H; Fattal E
    Adv Drug Deliv Rev; 2018 Sep; 134():122-137. PubMed ID: 30267743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy.
    Raj S; Khurana S; Choudhari R; Kesari KK; Kamal MA; Garg N; Ruokolainen J; Das BC; Kumar D
    Semin Cancer Biol; 2021 Feb; 69():166-177. PubMed ID: 31715247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticles for Cancer Targeting: Current and Future Directions.
    Swain S; Sahu PK; Beg S; Babu SM
    Curr Drug Deliv; 2016; 13(8):1290-1302. PubMed ID: 27411485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
    Danhier F
    J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy.
    Zhou Q; Dong C; Fan W; Jiang H; Xiang J; Qiu N; Piao Y; Xie T; Luo Y; Li Z; Liu F; Shen Y
    Biomaterials; 2020 May; 240():119902. PubMed ID: 32105817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Actively Targeted Nanoparticles for Drug Delivery to Tumor.
    Bi Y; Hao F; Yan G; Teng L; Lee RJ; Xie J
    Curr Drug Metab; 2016; 17(8):763-782. PubMed ID: 27335116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved Targeting of Cancers with Nanotherapeutics.
    Foster C; Watson A; Kaplinsky J; Kamaly N
    Methods Mol Biol; 2017; 1530():13-37. PubMed ID: 28150194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.